The first half of 2025 has seen an acceleration of M&A activity, including large-scale life sciences transactions, such as Merck’s $3.9 billion acquisition of SpringWorks, Sanofi’s $9.5 billion acquisition of Blueprint...more
8/14/2025
/ Acquisitions ,
Antitrust Litigation ,
Antitrust Provisions ,
Enforcement Actions ,
EU ,
European Commission ,
Hatch-Waxman ,
Johnson & Johnson ,
Life Sciences ,
Merger Controls ,
Mergers ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Regulatory Authority ,
Sanofi ,
Settlement Agreements ,
UK ,
UK Competition and Markets Authority (CMA)
In two recent public panels, the Department of Justice (DOJ) and the Federal Trade Commission (FTC) hosted the first of three joint listening sessions mandated by Executive Order No. 14273, Lowering Drug Prices by Once Again...more
7/14/2025
/ Antitrust Provisions ,
Biosimilars ,
Competition ,
Department of Justice (DOJ) ,
Drug Pricing ,
Federal Trade Commission (FTC) ,
Generic Drugs ,
Patent Litigation ,
Pharmaceutical Industry ,
Pharmacy Benefit Manager (PBM) ,
Prescription Drugs
While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the antitrust space in the first 100 days of the Trump administration....more
5/14/2025
/ AbbVie ,
Acquisitions ,
Antitrust Litigation ,
Antitrust Provisions ,
Cartwright Act ,
Consent Decrees ,
Drug Pricing ,
Federal Trade Commission (FTC) ,
Health Insurance ,
IP License ,
Life Sciences ,
Medical Devices ,
Merck ,
Mergers ,
Novo Nordisk ,
Pharmaceutical Industry ,
Pharmacy Benefit Manager (PBM) ,
Prescription Drugs